Effects of somatostatin analogues on human sphincter of Oddi pressure

What Was Tested

Researchers studied Octreotide and Somatostatin in this randomized controlled trial publication.

The aim of this study was to observe the action of stilamin and sandostatin on the sphincter of Oddi via choledochofiberscope manometry.

Why It Was Studied

Somatostatin, a neuropeptide and hormone, exists in the biliary tract of several species.

The effects of somatostatin and its analogues on the sphincter of Oddi motility have been controversial.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Twenty patients who had had "T" duct after cholecystectomy and choledochotomy were divided into 2 groups randomly: stilamin and sandostatin.

They were subjected to manometry via a choledochofiberscope through the "T" duct tract.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The following data recorded included duodenal pressure (DP), sphincter of Oddi basal pressure (SOBP), sphincter of Oddi contractive amplitude (SOCA), frequency of the sphincter of Oddi (SOF), duration of the sphincter of Oddi, and the common bile duct pressure (CBDP).

What Was Measured

PubMed files the paper under topics including Cholecystectomy, Choledocholithiasis, Gastrointestinal Motility, Manometry, Octreotide, Postoperative Period and Risk Assessment.

What This Means in Plain Language

The paper is a randomized study of Octreotide and Somatostatin.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Hepatobiliary & pancreatic diseases international : HBPD INT), a journal based in Singapore.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.